Trials of the Department of Pediatric Oncology, Heidelberg
The Department of Pediatric Oncology is an example for oncology in general, as virtually all children and adolescents with a malignant disease are treated in multicentric, national or international studies. This ensures that every child receives the best possible treatment available today and that the treatments are subject to very strict quality controls. It also allows us to constantly and systematically expand our knowledge, leading to a continuous improvement of treatment results. The trials are accredited by the Society for Pediatric Oncology and Hematology.
Moreover, we have initiated specific studies in Heidelberg that are coordinated in the network of the Society for Pediatric Oncology and Hematology.
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia
Phase III study for treatment of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis (TSC) with everolimus (EXIST-1)
Heavy ion radiotherapy in patients with non-resectable osteosarcoma OSCAR